Disease · MONDO_0005230

cellulitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cellulitis. Diseases, record MONDO_0005230. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005230

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cellulitis; Open Targets
Open Targets ID: MONDO_0005230; Open Targets
Other names: Bacterial infection of skin, Other cellulitis and abscess, Skin infection, cellulitis (disease); Open Targets
Disease Ontology: DOID:3488; Disease Ontology
MeSH: D002481; MeSH
NCI Thesaurus: C26715; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 21 drugs, from DailyMed; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PIPERACILLIN SODIUM	CHEMBL1200820	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TAZOBACTAM SODIUM	CHEMBL1439	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
FLOXACILLIN	CHEMBL222645	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TEDIZOLID PHOSPHATE	CHEMBL2105669	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CEFAZOLIN	CHEMBL1435	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MOXIFLOXACIN	CHEMBL32	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PROBENECID	CHEMBL897	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TRIMETHOPRIM	CHEMBL22	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
CEPHALEXIN	CHEMBL1200544	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
CLINDAMYCIN	CHEMBL1753	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Phase 2	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	1	Matrix metalloproteinase 7 inhibitor	Phase 2	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	1	Matrix metalloproteinase 8 inhibitor	Phase 2	https://conductscience.org/library/genes/4317	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6328	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00729937	Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"	Phase 2/3	2,265	2014-05-28	Staphylococcal Infection	CEPHALEXIN, CLINDAMYCIN, SULFAMETHOXAZOLE, TRIMETHOPRIM	Its record names the disease	ClinicalTrials.gov
NCT00730028	Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus	Phase 2	1,310	2016-03-17	Staphylococcal Infection	CLINDAMYCIN, SULFAMETHOXAZOLE, TRIMETHOPRIM	Its record names the disease	ClinicalTrials.gov
NCT01519778	A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study	Phase 2	200	2015-03-12	Major Cutaneous Abscess, Cellulitis, Erysipelas	TEDIZOLID PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT00676130	Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients	Not applicable	153	2012-08-14	Cellulitis	CEPHALEXIN, TRIMETHOPRIM	Its record names the disease	ClinicalTrials.gov
NCT02276482	Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)	Phase 3	120	2019-08-07	Skin Diseases, Infectious, Skin Diseases, Bacterial	TEDIZOLID PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT01981772	Efficacy of Buffered Lidocaine in Patients With Facial Swelling	Not applicable	88	2020-10-12	Orofacial Swelling	LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT01671423	Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis	Not applicable	42	2021-02-10	Cellulitis	PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00323219	Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department	Phase 3	390		Cellulitis	CEFAZOLIN, MOXIFLOXACIN, PROBENECID	Its record names the disease	ClinicalTrials.gov
NCT05584007	Cellulitis Optimal Antibiotic Treatment	Phase 3	334		Cellulitis of Leg	FLOXACILLIN	Its record names the disease	ClinicalTrials.gov
NCT03637400	Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment	Phase 2	269		Methicillin-resistant Staphylococcus Aureus, Skin Infection	DOXYCYCLINE, TRIMETHOPRIM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Trimethoprim-sulfamethoxazole vs Placebo: Relative Efficacy	62 of 73	60 of 73	146	NCT00676130	Trial comparisons
Trimethoprim-sulfamethoxazole vs Placebo: Progression to Abscess	5 of 73	5 of 73	146	NCT00676130	Trial comparisons
Trimethoprim-sulfamethoxazole vs Placebo: serious adverse events	0 of 73	1 of 73	146	NCT00676130	Trial comparisons
Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Investigator's Assessment Indicating Clinical Success at Test of Cure (TOC) Visit (Intent to Treat Analysis Set)	88 of 91	27 of 29	120	NCT02276482	Trial comparisons
Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Investigator's Assessment Indicating Clinical Success at End of Therapy (EOT) Visit (Intent to Treat Analysis Set)	88 of 91	28 of 29	120	NCT02276482	Trial comparisons
Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Early Clinical Responses Measured by Lesion Reduction	84 of 91	28 of 29	120	NCT02276482	Trial comparisons
Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs	13 of 91	3 of 29	120	NCT02276482	Trial comparisons
Tedizolid Phosphate vs Antibiotic Comparator Drug: deaths from any cause	0 of 91	0 of 29	120	NCT02276482	Trial comparisons
Tedizolid Phosphate vs Antibiotic Comparator Drug: serious adverse events	1 of 91	0 of 29	120	NCT02276482	Trial comparisons
Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Investigator's Assessment Indicating Clinical Success at EOT Visit (Clinically Evaluable-End of Therapy [CE-EOT] Analysis Set)	87 of 87	27 of 27	114	NCT02276482	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27530088	RESULT	1	PubMed
25785967	RESULT	1	PubMed
38211660	DERIVED	1	PubMed
33908631	DERIVED	1	PubMed
33395210	DERIVED	1	PubMed
31420292	DERIVED	1	PubMed
30926187	DERIVED	1	PubMed
30853250	DERIVED	1	PubMed
28987525	DERIVED	1	PubMed
28657870	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005230

GET https://conductscience.org/api/diseases/v1/MONDO_0005230/drugs?page=2

API reference For AI assistants